Large-cap Healthcare company Repligen has logged a -5.0% change today on a trading volume of 443,397. The average volume for the stock is 587,654.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Based in Waltham, United States the company has 1,852 full time employees and a market cap of $10,066,018,304.
The company is now trading -19.62% away from its average analyst target price of $225.55 per share. The 11 analysts following the stock have set target prices ranging from $180 to $270, and on average give Repligen a rating of buy.
Over the last year, RGEN shares have gone up 2.9%, which represents a difference of 10.6% when compared to the S&P 500. The stock's 52 week high is $262.26 per share whereas its 52 week low is $137.21. Based on Repligen's impressive sales and average gross margins growth of 2.1% over the last four years, its core business remains strong and the stock price may maintain this level of performance.
| 2019-12-31 | 2020-12-31 | 2021-12-31 | |
|---|---|---|---|
| Revenue (k) | $270,245 | $366,260 | $670,534 |
| Revenue Growth | n/a | 35.53% | 83.08% |
| Gross Margins | 55.9% | 57.2% | 58.4% |
| Gross Margins Growth | n/a | 2.33% | 2.1% |
| Operating Margins | 13.4% | 19.1% | 25.8% |
| Operating Margins Growth | n/a | 42.54% | 35.08% |
| Earnings Per Share | $0.44 | $1.11 | $2.24 |
| EPS Growth | n/a | 152.27% | 101.8% |
| Free Cash Flow (k) | $44,062 | $36,281 | $47,740 |
| FCF Growth | n/a | -17.66% | 31.58% |
| Capital Expenditures (k) | -$23,154 | -$26,344 | -$71,276 |
| Net Debt / EBITDA | -5.16 | -4.84 | -1.62 |
